Cancer biologics, also known as biological therapy or biotherapy, are medications designed to harness the power of the body’s immune system to fight cancer. Unlike chemotherapy which works through non-specific mechanisms, biologics have precise molecular targets relevant to cancer. These targets include growth factors, receptors, intracellular signaling molecules and immunologic checkpoint proteins. Some examples of molecular targets of cancer biologics are HER2, VEGF, EGFR, PD-1, PD-L1 etc.
Cancer continues to be one of the leading causes of mortality worldwide. As per market research report published on Coherent Market Insights, the global cancer biologics market is benefitted from research and development of newer treatment approaches provide hope for improved patient outcomes. Biologics have emerged as an important treatment modality against various cancer types. These biologic agents work by targeting specific molecules involved in cancer growth and progression. Let us take a deeper look at cancer biologics and their role in modern oncology.
Depending on their molecular targets and mechanisms of action, cancer biologics can be classified into the following major categories:
– Monoclonal Antibodies: These are antibodies engineered in the laboratory to target specific molecules on cancer cells or immune cells. Trastuzumab, Cetuximab, Bevacizumab are some examples.
– Cytokines: Cytokines like interleukins boost the immune system’s anti-tumor response. Interferons also have direct anti-proliferative effects on cancer cells.
– Cancer Vaccines: These train the immune system to recognize and attack cancer cells expressing specific antigens. Sipuleucel-T is an FDA approved cancer vaccine.
– Cell-based Immunotherapies: Chimeric antigen receptor T-cell (CAR-T) therapy and tumor-infiltrating lymphocyte (TIL) therapy utilize patient’s own immune cells after genetic modification to target cancer.
– Immune Checkpoint Inhibitors: These drugs like Nivolumab and Pembrolizumab help unleash the full potential of immune system by blocking inhibitory checkpoint molecules like PD-1, CTLA-4.
Role of Cancer Biologics in Different Cancer Types
The success of cancer biologics lies in their ability to revolutionize treatment outcomes for various malignancies. Let us explore their role in some major cancer types:
Breast Cancer
Trastuzumab (Herceptin) in combination with chemotherapy is now standard of care for HER2-positive breast cancer in both adjuvant and metastatic settings. It has significantly improved patient survival. Pertuzumab (Perjeta) is another approved anti-HER2 biologic.
Lung Cancer
Bevacizumab when added to chemotherapy is the first biologic approved for non-small cell lung cancer. It helps improve progression-free survival. PD-1 inhibitors like Pembrolizumab and Nivolumab provide durable responses in advanced NSCLC, small cell lung cancer and mesothelioma.
Colorectal Cancer
Cetuximab and Panitumumab are Epidermal Growth Factor Receptor (EGFR) inhibitors approved as treatment options for metastatic colorectal cancer. Bevacizumab is also used along with chemotherapy.
Gastrointestinal Cancers
Trastuzumab emtansine (Kadcyla) is approved for gastric and gastroesophageal junction cancers expressing HER2. Ramucirumab targets VEGFR-2 and improves survival in gastric and colorectal cancers.
Prostate Cancer
Sipuleucel-T immunotherapy helps extend survival in late-stage metastatic prostate cancer.
Immuno-Oncology Revolution powered by Cancer Biologics
Cancer biologics have completely transformed the landscape of cancer treatment by empowering the immune system to destroy tumor cells. Immune checkpoint inhibitors like anti-PD-1 and anti-CTLA4 agents have produced durable clinical responses across several previously untreatable cancer types. The amazing potential of CAR-T cell therapies is redefining leukemia and lymphoma treatment. Combination strategies involving biologics, small molecule drugs and other modalities promise even brighter future. The era of immuno-oncology is upon us powered by precision biologic agents.
Market Outlook
The advent of novel biologic agents that modulate the immune system against cancer has revolutionized modern oncology. The global cancer biologics market is expected to witness high growth in the coming years driven by factors like increasing cancer prevalence, higher research funding, rapid drug approvals, surging demand and commercial success of products. While the United States currently dominates the worldwide market, Asia Pacific region is emerging as an attractive destination due to rising healthcare investments, improved access and growing middle-class population. Though costly in the short-term, cancer biologics provide long-term savings by improving clinical outcomes and quality of life for patients. Their arrival has filled the oncology community with hope and optimism to continue the progress against this once incurable disease. For more details, refer the market analysis report published by Coherent Market Insights.
